secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bicara Therapeutics Inc. (BCAX)
CIK:        0002023658
Form:       8-K
Filed at:   2025-03-27T23:59:59+00:00
Accession:  0002023658-25-000006
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bicara Therapeutics reports Q4 net loss $21M, cash $489.7M; pivotal Phase 2/3 trial dosing started
--------------------------------------------------------------------------------

- Net loss $21.0M in Q4 2024, $68.0M full year; vs $12.4M and $52.0M in 2023.
- Cash and equivalents $489.7M as of Dec 31, 2024, up from $230.4M; funds operations into first half 2029.
- First patients dosed in February 2025 in FORTIFI-HN01, pivotal Phase 2/3 trial of ficerafusp alfa in 1L R/M HNSCC.
- Updated Phase 1/1b data for ficerafusp alfa in 1L R/M HNSCC to be presented at 2025 ASCO Annual Meeting.
- Three abstracts on ficerafusp alfa accepted for AACR 2025, including monotherapy in cSCC and preclinical lung cancer data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2023658/000202365825000006/0002023658-25-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2023658/000202365825000006/bcax-20250327.htm
  HTML page:      https://secwatch.observer/filing/0002023658-25-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer